CALC (CalciMedica) LT-Debt-to-Total-Asset: 0.49 (As of Mar. 2026)


CALC CalciMedica Inc CALC
23 GF Score
Price $0.79
! 2 Warning Signs
View Full Analysis

What is CalciMedica LT-Debt-to-Total-Asset?

CalciMedica CALC +29.67% 23 LT-Debt-to-Total-Asset is 0.49 as of Mar. 2026. GuruFocus rates CALC with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CalciMedica's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.49.

CalciMedica's long-term debt to total assets ratio increased from Mar. 2025 (0.34) to Mar. 2026 (0.49). It may suggest that CalciMedica is progressively becoming more dependent on debt to grow their business.

CalciMedica  (NAS:CALC) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CalciMedica LT-Debt-to-Total-Asset Related Terms

CalciMedica LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for CalciMedica's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CalciMedica LT-Debt-to-Total-Asset Chart

CalciMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.00 1.54 0.00 0.00 0.62

CalciMedica Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.45 0.60 0.62 0.49
CALC
23GF Score
CalciMedica Inc CALC
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CalciMedica LT-Debt-to-Total-Asset Calculation

CalciMedica's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=8.45/13.591
=

CalciMedica's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=4.2/8.609
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.49 mean?
CalciMedica (CALC) has a LT-Debt-to-Total-Asset of 0.49 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CalciMedica and its competitors.
Is CalciMedica's LT-Debt-to-Total-Asset too high?
CalciMedica's current LT-Debt-to-Total-Asset is 0.49. Overall, CalciMedica has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does CalciMedica's LT-Debt-to-Total-Asset compare to TOVX and PHIO?
CalciMedica's LT-Debt-to-Total-Asset of 0.49 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CalciMedica and its competitors. CalciMedica's current LT-Debt-to-Total-Asset is 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CalciMedica stock overvalued right now?
CalciMedica (CALC) has a current LT-Debt-to-Total-Asset of 0.49. The current LT-Debt-to-Total-Asset is 0.49. CalciMedica's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For CalciMedica (CALC), the current LT-Debt-to-Total-Asset is 0.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CalciMedica Business Description

Address 505 Coast Boulevard South, Suite 307, La Jolla, CA, USA, 92037
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
23GF Score

Get the complete analysis for CALC

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.79
Price